We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Novartis Expands Pain Portfolio with Spinifex Acquisition
Novartis Expands Pain Portfolio with Spinifex Acquisition
Swiss drugmaker Novartis is upping its stakes in the chronic pain market with the purchase of U.S.-Australian drugmaker Spinifex Pharmaceuticals for $200 million plus undisclosed milestone payments.